Clinical Trials Browser

OTHER × trilaciclib × 1 year × Clear all

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06027268 2026-02-03

ToPCourT

Phase 2 Active not recruiting

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05578326 2025-07-08

Study of Trilaciclib and Lurbinectidin

Phase 2 Recruiting

Lung Neoplasms, Neutropenia, Small Cell Lung Carcinoma

NCT06992739 2025-05-28

PROTECT-2

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06955156 2025-05-02

Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC

Phase 2 Recruiting

Triple Negative Breast Neoplasms